Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

30.9K
Overview
30.9K
Viral Mutations00:36

Viral Mutations

32.1K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing the zoonotic threat of merbecoviruses.

Nature microbiology·2026
Same author

Identification and characterization of novel chikungunya virus polymerase inhibitors.

Journal of virology·2026
Same author

Spike conformational tuning rather than epitope erosion drives SARS-CoV-2 resistance to broadly neutralizing antibodies.

bioRxiv : the preprint server for biology·2026
Same author

The ability of alphavirus replicases to synthesize non-viral type I interferon-inducing RNAs correlates with viral RNA synthesis and has a diverse impact on virus replication and pathogenicity.

Journal of virology·2026
Same author

Trans-complementation of chikungunya virus replicase mutants reveals alphavirus replication complexity and supports antiviral tool development.

PLoS pathogens·2025
Same author

Antiviral Activity of Liposomes Containing Natural Compounds Against CHIKV.

Pharmaceutics·2025
Same journal

Correction: Jiménez-Sánchez et al. Antioxidant Enzymes Genetic Variants Associated with Urticaria/Angioedema Induced by Cross-Reactive Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs. <i>Pharmaceuticals</i> 2026, <i>19</i>, 522.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Correction: Zhao et al. Multifunctional Gel Films of Marine Polysaccharides Cross-Linked with Poly-Metal Ions for Wound Healing. <i>Pharmaceuticals</i> 2022, <i>15</i>, 750.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Intravenous Immunoglobulin Reveals a Novel Protective Mechanism: Targeting the GBP5-Driven Pyroptosis Axis in Experimental Colitis.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Icariin Attenuates Renal Injury in Streptozotocin-Induced Diabetic Rats with and Without Adenine-Induced Chronic Kidney Disease.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

AI-Assisted Identification of a Putative Allosteric Ligand Targeting the CDK4/Cyclin D1 Protein-Protein Interface.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Development and Study of Hydrophilic Ointment Compositions with a Dextrin/Polyvinyl Alcohol/Iodine Complex (D/PVA/I).

Pharmaceuticals (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: May 20, 2025

Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

13.9K

Dengue Virus Inhibitors as Potential Broad-Spectrum Flavivirus Inhibitors.

Larisa Ivanova1, Krystyna Naumenko2,3, Margus Varjak4

  • 1Institute of Chemistry, University of Tartu, Ravila 14A, 50411 Tartu, Estonia.

Pharmaceuticals (Basel, Switzerland)
|March 27, 2025
PubMed
Summary
This summary is machine-generated.

Several compounds previously shown to inhibit Dengue virus (DENV) also inhibit other flaviviruses, including Zika virus (ZIKV). This study identifies new broad-spectrum antiviral agents and confirms experimental findings for TBEV inhibitors.

Keywords:
broad-spectrum inhibitorsflavivirusesmolecular dynamics simulation

More Related Videos

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction
08:36

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction

Published on: November 1, 2018

31.7K
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

13.7K

Related Experiment Videos

Last Updated: May 20, 2025

Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

13.9K
Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction
08:36

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction

Published on: November 1, 2018

31.7K
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

13.7K

Area of Science:

  • Virology
  • Drug Discovery
  • Molecular Biology

Background:

  • Flaviviruses pose a global health threat due to their widespread transmission and lack of effective treatments.
  • The emergence of flaviviral diseases necessitates the development of novel antiviral therapies.
  • Identifying broad-spectrum inhibitors is crucial for combating diverse flaviviral infections.

Purpose of the Study:

  • To evaluate previously identified Dengue virus (DENV) inhibitors for activity against other flaviviruses.
  • To discover potential broad-spectrum antiviral agents for flaviviral infections.
  • To investigate the anti-TBEV activity of specific compounds.

Main Methods:

  • Cytotoxicity assays (WST-1) to determine compound safety.
  • Inhibition assays against Dengue virus 2 (DENV2), Zika virus (ZIKV), Kunjin virus (KUNV), and Tick-borne encephalitis virus (TBEV).
  • Replicon-based assays and molecular dynamics simulations for active compounds.

Main Results:

  • Two of eight DENV2/DENV4 inhibitors showed broad-spectrum activity against all tested flaviviruses at low micromolar concentrations.
  • Compound C6 inhibited both DENV2 and TBEV.
  • Lycorine (C1), mycophenolic acid (C3), and vidarabine (C7) were identified as novel TBEV inhibitors.

Conclusions:

  • Compounds effective against DENV can also inhibit other flaviviruses, highlighting potential broad-spectrum applications.
  • This study provides the first report of anti-TBEV activity for lycorine, mycophenolic acid, and vidarabine.
  • Experimental validation is essential, as demonstrated by the confirmation of C5's antiviral activity and C8's lack thereof.